Vivo Bio Tech Board of Directors
Get the latest insights into the leadership at Vivo Bio Tech. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. M Kalyan Ram | Whole Time Director |
| Dr. Alangudi Sankaranarayanan | Whole Time Director |
| Mr. Sri Kalyan Kompella | WholeTime Director & CFO |
| Mrs. Kunda Kalpana | Ind. Non-Executive Director |
| Dr. Shivanand Nayak Karopadi | Non Executive Director |
| Mr. Shyam Sunder Tipparaju | Ind. Non-Executive Director |
Vivo Bio Tech Share price
VIVOBIOT
32.88
0.05 (-0.15%)Last updated on 3 Nov, 2025 | 15:50 IST
BUYSELL
Today's High
33.48
Today's Low
32.80
52 Week Low
31.20
52 Week High
56.90
The current prices are delayed, login to your account for live prices
LoginVivo Bio Tech FAQs
The board at Vivo Bio Tech consists of experienced professionals, including Mr. M Kalyan Ram , Dr. Alangudi Sankaranarayanan , and others, overseeing the company’s strategic and corporate governance.
Directors at Vivo Bio Tech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. M Kalyan Ram is the current chairman at Vivo Bio Tech.
Executive directors at Vivo Bio Tech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Vivo Bio Tech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Vivo Bio Tech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.